ClinicalTrials.gg
CompletedNCT02038920Updated Dec 9, 2019Results posted

Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease

A Phase 3 interventional study of Vedolizumab and Vedolizumab placebo in Crohn's Disease, sponsored by Takeda. Completed at 56 sites in Japan. Open to participants aged 15 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-12-09.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
15 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Enrollment
16th of 39
157 · median 101
Started
2014
with 1 other
Phase 3
16 of 39
6 open now
Registered
6th of 39
by date
Lead sponsor
25 of 39
Takeda

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 16th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 6th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 15 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in Japanese participants with moderately or severely active Crohn's disease.

Read the detailed description

This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous vedolizumab (300 mg) infusion in induction and maintenance therapy in Japanese participants with moderately or severely active Crohn's disease.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
15 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, participants were capable of understanding and complying with protocol requirements
  2. Participants or, when applicable, participants legally acceptable representative sign and date the form prior to initiation of any study procedures
  3. Participants aged 15 to 80 years (inclusive) at the time of consent
  4. A nonsterilized male participant who has a female partner of has to agree to use adequate during the period from the signing of informed consent to 6 months after the last dose of the study drug
  5. A female participant of child-bearing potential (i.e., nonsterilized or whose last regular menses was within previous 2 years) who has a nonsterilized male partner has to agree to use adequate contraception during the period from the signing of informed consent to 6 months after the last dose of the study drug
  6. Participants with a diagnosis of small-intestinal, large-intestinal, or small-/large-intestinal Crohn's disease (CD) established based on the Revised Diagnostic Criteria for Crohn's disease issued by Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease by the Ministry of Health, Labor and Welfare of Japan (2012) at least 3 months before the start of administration of study drug
  7. Participants with baseline CDAI score of 220 to 450(inclusive) and meeting at least one of the followings:

    • C-reactive protein (CRP) at screening test is above 0.30 mg/dL
    • Participants with irregular or semicircular ulcers or multiple aphthae (10 or more) observed over an extensive area of the small or large intestine on endoscopy or imaging test within the 4 months before the start of administration of study drugs
    • Participants with longitudinal ulcers or a cobblestone appearance observed in the small or large intestine on endoscopy or imaging test within 4 months before the start of administration of study drugs
  8. In case of the participants who meet any of the following criteria; participants with ≥ 8-year history of extensive or limited colitis, participants aged ≥ 50 years, or participants with a first-degree family history of colon cancer, those whom the complication of colon cancer or dysplasia was ruled out by total colonoscopy at the start of study drug administration (or the results from total colonoscopy performed within 1 year before giving consent are available)
  9. Participants meeting the criteria for treatment failure below with at least one of the following agents received within previous 5 year period before giving consent

      • Resistance
      • Dependence
      • Intolerance
    1. Immunomodulators (azathioprine, 6-mercaptopurine or methotrexate)

      • Intolerance
    2. Anti-tumor necrosis factor alpha (TNFα) antibodies

      • Inadequate response
      • Loss of response
      • Intolerance

Exclusion criteria

Exclusion Criteria:

  1. Participants with an evidence of or suspected abdominal abscess
  2. Participants with a history of subtotal or total colectomy
  3. Participants who have had a resection of the small intestine in at least 3 locations or have a diagnosis of short bowel syndrome
  4. Participants with ileostomy, colostomy, or internal fistula, or severe intestinal stenosis
  5. Participants who have a treatment history with natalizumab, efalizumab or rituximab
  6. Participants who started 5-aminosalicylic acid oral drug or probiotics treatment, antimicrobials to treat Crohn's disease, or 30 mg/day or less of oral within 13 days before initiation of study drug administration. If these drugs were used within 14 days before initiation of study drug administration, the dosage must have been changed or their use discontinued within 13 days before the initiation of study drug administration
  7. Participants who had received 5-aminosalicylic acid or corticosteroid enemas/suppositories, intravenous corticosteroid injections, or more than 30 mg/day of oral corticosteroids, medications for diarrhea-predominant irritable bowel syndrome, or Chinese herbal medicine for the treatment of Crohn's disease (e.g., Daikenchuto) within 13 days before initiation of study drug administration
  8. Participants who had received azathioprine, 6-mercaptopurine, or methotrexate within 27 days before initiation of study drug administration. However, this shall not apply to participants who have received these drugs for 83 or more days before initiation of the study drug administration and continued the steady dose administration of the drugs for 27 or more days before initiation of the study drug administration
  9. Participants who had received cyclosporin, tacrolimus, tofacitinib or any study drugs for treatment of ulcerative colitis within 27 days before initiation of the study drug administration
  10. Participants who had received adalimumab within 27 days before initiation of study drug administration or any biological drugs other than adalimumab within 55 days before initiation of study drug administration. Topical administration (such as intraocular implantation for treatment of age-related maculopacy) is allowed
  11. Participants who had received any within 27 days before initiation of study drug administration
  12. Participants who had undergone intestinal resection within 27 days before initiation of study drug administration or those anticipated to require intestinal resection during the study
  13. Participants who had received leukocytapheresis or granulocyte apheresis within 27 days before initiation of the study drug administration
  14. Participants who had received intravenous hyperalimentation or total enteral nutrition within the 20 days before initiation of the study drug administration or participants who are fasted
  15. Participants who had received enteral nutrition at > 900 kcal/day or started enteral nutrition at \<= 900 kcal/day within the 20 days before initiation of the study drug administration. Participants receiving 900 kcal/day or less of enteral nutrition for at least 21 days before initiation of the study drug administration whom these dosage was changed or the medications were discontinued within 20 days before initiation of the study drug administration
  16. Participants who had been infected with Clostridium difficile, cytomegalovirus, or any other intestinal pathogen within 27 days before the first dose of the study drug
  17. Participants with evidence of adenomatous colonic polyps that need to be removed at the start of study drug administration
  18. Participants with a history or an complication of dysplasia of the small or large intestine
  19. Participants who were suspected to have enteritis other than CD
  20. Participants who were surface (HBs) antigen-positive or virus (HCV) antibody-positive at the screening. Or participants who are hepatitis B core (HBc) antibodypositive or HBs antibody positive, even though HBs antigen-negative. However, this does not apply to participants who are only HBs antibody-positive due to hepatitis B virus (HBV) vaccination, HBV-DNA-negative, HCV antigen-negative, or HCV-RNA-negative
  21. Participants who had an evidence of history of tuberculosis or a suspected history of tuberculosis (including those who have findings suggesting previous tuberculosis on chest imaging procedure at the screening). However, this does not apply to participants who had completed prophylactic isoniazid, or participants who had been receiving prophylactic isoniazid for more than 21 days before the first dose of the study drug (in the latter case, the screening period are allowed to extend up to 28 days to ensure at least 21-day prophylactic isoniazid and then the study treatment is allowed to start)
  22. Participants who had positive T-SPOT test or QuantiFERON test at the screening
  23. Participants who had a history or complication of identified congenital or acquire immunodeficiency syndrome (eg, not-classifiable immunodeficiency, [HIV] infection or organ transplantation)
  24. Participants who had been affected by extraintestinal infection (eg, pneumonia, sepsis, active hepatitis or pyelonephritis) within 27 days before the first dose of the study drug
  25. Participants who had a treatment history with MLN0002
  26. Female participants who are lactating at the screening, or have positive urine pregnancy test either at the screening or baseline
  27. Participants who had serious complications in the heart, lung, liver, kidney, metabolism, gastrointestinal system, urinary system, endocrine system or blood
  28. Participants who had a history of a surgery requiring general anesthesia within 27 days before the first dose of the study drug, or with a schedule of a surgery requiring hospitalization during the study period
  29. Participants who had a complication or a history of . However, this does not apply to the following participants:

    • Participants who had a curative resection of localized skin basal cell carcinoma or have completed curative radiotherapy
    • Participants who had not experienced recurrence for more than 1 year since completion of a curative resection or curative radiotherapy for skin squamous cell carcinoma
    • Participants who had not experienced recurrence for more than 3 years since completion of a curative resection or curative radiotherapy for intraepithelial carcinoma of uterine cervix For participants who had a substantially distant history of malignancy (eg, 10 years or longer without recurrence since treatment completion), the investigator and the sponsor had a discussion to decide eligibility on the basis of type of malignancy and treatment applied
  30. Participants who had a history or a complication of the central nervous disorder, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  31. Participants who had any subjective symptoms in the subjective PML checklist at the screening or baseline
  32. Participants who had any of the following laboratory abnormalities at the screening;

    • ≤8 g/dL
    • White blood cells ≤3,000/μL
    • Lymphocytes ≤500/μL
    • ≤100,000/μL or ≥1,200,000/μL
    • (ALT) or aspartate aminotransferase (AST) ≥3× (ULN)
    • Alkaline phosphatase (ALP) ≥3×ULN
    • Creatinine ≥2×ULN
  33. Participants who had a history or a complication of alcohol dependence or illicit drug use within one year before the first dose of the study drug
  34. Participants who had a history or a complication of psychotic disorder that could obstruct compliance with the study procedures
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Induction Phase: Vedolizumab, 300 mg

    Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.

    Drug: Vedolizumab

  • Placebo comparator
    Induction Phase: Placebo

    Vedolizumab placebo-matching IV infusion once at Weeks 0, 2 and 6 in the induction phase.

    Drug: Vedolizumab placebo

  • Experimental
    Maintenance Phase: Vedolizumab 300 mg

    Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved Crohn's Disease Activity Index (CDAI)-70 response at Week 10 and were randomized to receive vedolizumab in maintenance phase.

    Drug: Vedolizumab

  • Placebo comparator
    Maintenance Phase: Placebo

    Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved CDAI-70 response at Week 10 and were randomized to receive placebo in maintenance phase.

    Drug: Vedolizumab placebo

  • Placebo comparator
    Maintenance Phase: Placebo Continuation

    Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved CDAI-70 response at Week 10 received placebo in maintenance phase without randomization.

    Drug: Vedolizumab placebo

  • Experimental
    Open-Label: Vedolizumab 300 mg

    Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 as a maximum duration in open-label phase.

    Drug: Vedolizumab

Interventions

  • Vedolizumab IV injection

    Also known as: MLN0002

  • DrugVedolizumab placebo

    Vedolizumab placebo-matching IV infusion

06

What researchers measure

Primary outcomes

  1. Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response

    A response to therapy is considered a decrease from baseline of at least 100 points in the CDAI score at Week 10. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

    Time frame: Week 10

  2. Maintenance Phase: Percentage of Participants With Clinical Remission

    Clinical remission is defined as the CDAI score ≤150. CDAI is scoring system for the assessment of Crohn's disease activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

    Time frame: Week 60

  3. Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)

    An Adverse event (AE) is defined as any untoward medical occurrence in a study participant who received a drug (including a study drug); it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  4. Number of Participants With TEAE Related to Body Weight (Weight Decreased)

    Reported events on this outcome measure were "Weight Decreased".

    Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  5. Number of Participants With TEAE Related to Vital Signs

    Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm). Reported events on this outcome measure were "Pyrexia", "Body temperature increased", "Hypertension", and "Orthostatic hypotension".

    Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  6. Number of Participants With TEAE Related to Electrocardiogram (ECG) [Bundle Branch Block Right]

    Reported events on this outcome measure were "Bundle Branch Block Right".

    Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

  7. Number of Participants With Markedly Abnormal Values of Laboratory Parameters Values

    The laboratory values outside the range (Hemoglobin \<=7 g/dL, Lymphocytes \<500 /microL, White Blood Cell (WBC) \<2000 /microL, Platelets \<7.5 10\^4/microL, Neutrophils \<1000 /microL, Alanine Aminotransferase (ALT) (Glutamic Pyruvic Transaminase; GPT) \>3.0 U/L x upper limit of normal (ULN), Aspartate Aminotransferase (AST) (Glutamic Oxaloacetic Transaminase; GOT) \>3.0 U/L x ULN, Total Bilirubin \>2.0 mg/dL x ULN, Amylase \>2.0 (U/L) x ULN are considered markedly abnormal.

    Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

Secondary outcomes

  1. Induction Phase: Percentage of Participants With Clinical Remission

    Clinical remission is defined as the CDAI score ≤150. CDAI is scoring system for the assessment of Crohn's disease activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

    Time frame: Week 10

  2. Induction Phase: Change From Baseline in C-reactive Protein (CRP) Values

    Time frame: Baseline to Week 10

  3. Maintenance Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response

    A response to therapy is considered a decrease from baseline of at least 100 points in the CDAI score at Week 10. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

    Time frame: Week 60

  4. Maintenance Phase: Percentage of Participants With Durable Clinical Remission

    Durable clinical remission is defined as participants with CDAI score ≤ 150 at both Weeks 14 and 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

    Time frame: From Week 14 and Week 60

  5. Maintenance Phase: Percentage of Participants With Corticosteroid-free Clinical Remission

    Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

    Time frame: Week 60

  6. Serum Vedolizumab Concentration in Induction Phase

    Time frame: Weeks 2, 6, 10 and 14

  7. Serum Vedolizumab Concentration in Maintenance Phase

    Time frame: Weeks 2, 6, 10, 14, 22, 30 and 60

  8. Number of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase

    Time frame: Weeks 0, 10 and 16 weeks after the last dose of study drug in induction phase

  9. Number of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase

    Time frame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug in maintenance phase

  10. Number of Participants With Anti-vedolizumab Antibodies (AVA) in Open Label Cohort

    Time frame: Weeks 0, 10, 30, 62, 94 and 16 weeks after the last dose of study drug in open-label cohort

  11. Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase

    Time frame: Weeks 0, 10 and 16 weeks after the last dose of study drug in induction phase

  12. Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase

    Time frame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug in maintenance phase

  13. Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Open Label Cohort

    Time frame: Weeks 0, 10, 30, 62, 94 and 16 weeks after the last dose of study drug in open-label cohort

07

Results

Posted Dec 9, 2019

Participant flow

Participants took part in the study at 77 investigative sites in Japan from 28 Jan 2014 to 21 May 2019.

Induction Phase (Week 0 to 14)
Participant flow — Induction Phase (Week 0 to 14)
MilestoneInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
Started79780000
Completed73660000
Not completed6120000
Withdrew: Pretreatment event/adverse event3110000
Withdrew: Voluntary withdrawal200000
Withdrew: Lack of efficacy110000
Maintenance Phase (Week 14 to 60)
Participant flow — Maintenance Phase (Week 14 to 60)
MilestoneInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
Started001212170
Completed007450
Not completed0058120
Withdrew: Pretreatment event/adverse event002420
Withdrew: Lost to follow-up001000
Withdrew: Lack of efficacy0024100
Open Label Cohort (Week 10 to 154)
Participant flow — Open Label Cohort (Week 10 to 154)
MilestoneInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
Started00000134
Completed0000057
Not completed0000077
Withdrew: Pretreatment event/adverse event0000043
Withdrew: Lost to follow-up000001
Withdrew: Voluntary withdrawal000007
Withdrew: Pregnancy000001
Withdrew: Lack of efficacy0000023
Withdrew: Reason not specified000002

Outcome measures

PrimaryInduction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response

A response to therapy is considered a decrease from baseline of at least 100 points in the CDAI score at Week 10. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response
percentage of participantsInduction Phase: Vedolizumab, 300 mgInduction Phase: Placebo
Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response26.6 (17.268 to 37.720)16.7 (9.184 to 26.813)
Statistical analysis
  • Induction Phase: Vedolizumab, 300 mg vs Induction Phase: Placebo · Cochran-Mantel-Haenszel · p = 0.1448 · Odds ratio (or): 1.80 · 95% CI 0.816 to 3.958MLN0002 group/placebo group. Cochran-Mantel-Haenszel (CMH) test was used for analysis. Prior tumor necrosis factor alpha (TNFα) antagonist use (yes/no) was used as stratification factor.
PrimaryMaintenance Phase: Percentage of Participants With Clinical Remission

Clinical remission is defined as the CDAI score ≤150. CDAI is scoring system for the assessment of Crohn's disease activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Time frame:
Week 60
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Clinical Remission
percentage of participantsMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo
Maintenance Phase: Percentage of Participants With Clinical Remission41.7 (15.165 to 72.333)16.7 (2.086 to 48.414)
Statistical analysis
  • Maintenance Phase: Vedolizumab 300 mg vs Maintenance Phase: Placebo · Pearson's Chi-square Test · p = 0.1779 · Odds ratio (or): 3.57 · 95% CI 0.532 to 23.953MLN0002 group/placebo group
PrimaryNumber of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)

An Adverse event (AE) is defined as any untoward medical occurrence in a study participant who received a drug (including a study drug); it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)
ParticipantsInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)494291012130
PrimaryNumber of Participants With TEAE Related to Body Weight (Weight Decreased)

Reported events on this outcome measure were "Weight Decreased".

Time frame:
From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAE Related to Body Weight (Weight Decreased)
ParticipantsInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
Number of Participants With TEAE Related to Body Weight (Weight Decreased)000002
PrimaryNumber of Participants With TEAE Related to Vital Signs

Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm). Reported events on this outcome measure were "Pyrexia", "Body temperature increased", "Hypertension", and "Orthostatic hypotension".

Time frame:
From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAE Related to Vital Signs
ParticipantsInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
Pyrexia3101119
Body Temperature Increased100000
Hypertension001001
Orthostatic Hypotension000001
PrimaryNumber of Participants With TEAE Related to Electrocardiogram (ECG) [Bundle Branch Block Right]

Reported events on this outcome measure were "Bundle Branch Block Right".

Time frame:
From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With TEAE Related to Electrocardiogram (ECG) [Bundle Branch Block Right]
ParticipantsInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
Number of Participants With TEAE Related to Electrocardiogram (ECG) [Bundle Branch Block Right]000001
PrimaryNumber of Participants With Markedly Abnormal Values of Laboratory Parameters Values

The laboratory values outside the range (Hemoglobin \<=7 g/dL, Lymphocytes \<500 /microL, White Blood Cell (WBC) \<2000 /microL, Platelets \<7.5 10\^4/microL, Neutrophils \<1000 /microL, Alanine Aminotransferase (ALT) (Glutamic Pyruvic Transaminase; GPT) \>3.0 U/L x upper limit of normal (ULN), Aspartate Aminotransferase (AST) (Glutamic Oxaloacetic Transaminase; GOT) \>3.0 U/L x ULN, Total Bilirubin \>2.0 mg/dL x ULN, Amylase \>2.0 (U/L) x ULN are considered markedly abnormal.

Time frame:
From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Values of Laboratory Parameters Values
ParticipantsInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
Hemoglobin (g/dL) <=7010004
Lymphocytes (/uL) <5007612118
WBC (/uL) <2000000001
Platelets (10^4/uL) <7.5000001
Neutrophils (/uL) <1000000001
ALT (GPT) (U/L) >3.0 x ULN110001
AST (GOT) (U/L) >3.0 x ULN100001
Total Bilirubin (mg/dL) >2.0 x ULN000004
Amylase (U/L) >2.0 x ULN100008
SecondaryInduction Phase: Percentage of Participants With Clinical Remission

Clinical remission is defined as the CDAI score ≤150. CDAI is scoring system for the assessment of Crohn's disease activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Induction Phase: Percentage of Participants With Clinical Remission
percentage of participantsInduction Phase: Vedolizumab, 300 mgInduction Phase: Placebo
Induction Phase: Percentage of Participants With Clinical Remission17.7 (10.041 to 27.942)10.3 (4.533 to 19.213)
Statistical analysis
  • Induction Phase: Vedolizumab, 300 mg vs Induction Phase: Placebo · Cochran-Mantel-Haenszel · p = 0.1963 · Odds ratio (or): 1.83 · 95% CI 0.720 to 4.673MLN0002 group/placebo group. Cochran-Mantel-Haenszel (CMH) test was used for analysis. Prior tumor necrosis factor alpha (TNFα) antagonist use (yes/no) was used as stratification factor.
SecondaryInduction Phase: Change From Baseline in C-reactive Protein (CRP) Values
Time frame:
Baseline to Week 10
Reported as:
Mean · mg/dL
Induction Phase: Change From Baseline in C-reactive Protein (CRP) Values
mg/dLInduction Phase: Vedolizumab, 300 mgInduction Phase: Placebo
Change from Baseline at Week 20.022 ± 2.1421-0.125 ± 2.8417
Change from Baseline at Week 6-0.089 ± 2.02660.130 ± 2.1674
Change from Baseline at Week 10-0.164 ± 2.27290.077 ± 2.8690
SecondaryMaintenance Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response

A response to therapy is considered a decrease from baseline of at least 100 points in the CDAI score at Week 10. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Time frame:
Week 60
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response
percentage of participantsMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo
Maintenance Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response58.3 (27.667 to 84.835)8.3 (0.211 to 38.480)
Statistical analysis
  • Maintenance Phase: Vedolizumab 300 mg vs Maintenance Phase: Placebo · Pearson's Chi-square Test · p = 0.0094 · Odds ratio (or): 15.40 · 95% CI 1.473 to 160.972
SecondaryMaintenance Phase: Percentage of Participants With Durable Clinical Remission

Durable clinical remission is defined as participants with CDAI score ≤ 150 at both Weeks 14 and 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Time frame:
From Week 14 and Week 60
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Durable Clinical Remission
percentage of participantsMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo
Maintenance Phase: Percentage of Participants With Durable Clinical Remission33.3 (9.925 to 65.112)25.0 (5.486 to 57.186)
Statistical analysis
  • Maintenance Phase: Vedolizumab 300 mg vs Maintenance Phase: Placebo · Pearson's Chi-square Test · p = 0.6534 · Odds ratio (or): 1.50 · 95% CI 0.254 to 8.844MLN0002 group/placebo group.
SecondaryMaintenance Phase: Percentage of Participants With Corticosteroid-free Clinical Remission

Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Time frame:
Week 60
Reported as:
Number · percentage of participants
Maintenance Phase: Percentage of Participants With Corticosteroid-free Clinical Remission
percentage of participantsMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo
Maintenance Phase: Percentage of Participants With Corticosteroid-free Clinical Remission40.0 (5.274 to 85.337)0.0 (0.000 to 70.760)
Statistical analysis
  • Maintenance Phase: Vedolizumab 300 mg vs Maintenance Phase: Placebo · Pearson's Chi-square Test · p = 0.2059
SecondarySerum Vedolizumab Concentration in Induction Phase
Time frame:
Weeks 2, 6, 10 and 14
Reported as:
Mean · ug/mL
Serum Vedolizumab Concentration in Induction Phase
ug/mLInduction Phase: Vedolizumab, 300 mg
Week 228.23 ± 11.018
Week 621.01 ± 14.076
Week 1022.31 ± 14.049
Week 1412.24 ± 10.350
SecondarySerum Vedolizumab Concentration in Maintenance Phase
Time frame:
Weeks 2, 6, 10, 14, 22, 30 and 60
Reported as:
Mean · ug/mL
Serum Vedolizumab Concentration in Maintenance Phase
ug/mLMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo
Week 229.32 ± 13.88030.54 ± 9.7495
Week 625.19 ± 17.05424.90 ± 14.490
Week 1026.24 ± 15.46426.60 ± 15.642
Week 1411.20 ± 8.579313.72 ± 13.072
Week 229.102 ± 6.18091.502 ± 2.8285
Week 309.013 ± 6.87740.000 ± 0.0000
Week 6013.68 ± 4.26590.000 ± 0.0000
SecondaryNumber of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase
Time frame:
Weeks 0, 10 and 16 weeks after the last dose of study drug in induction phase
Reported as:
Count of participants · Participants
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase
ParticipantsInduction Phase: Vedolizumab, 300 mg
Week 01
Week 101
16 Weeks After Last Administration0
SecondaryNumber of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
Time frame:
Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug in maintenance phase
Reported as:
Count of participants · Participants
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
ParticipantsMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo
Week 000
Week 1000
Week 3002
Week 6001
16 Weeks After Last Administration00
SecondaryNumber of Participants With Anti-vedolizumab Antibodies (AVA) in Open Label Cohort
Time frame:
Weeks 0, 10, 30, 62, 94 and 16 weeks after the last dose of study drug in open-label cohort
Reported as:
Count of participants · Participants
Number of Participants With Anti-vedolizumab Antibodies (AVA) in Open Label Cohort
ParticipantsOpen-Label: Vedolizumab 300 mg
Week 02
Week 102
Week 302
Week 620
Week 940
16 Weeks After Last Administration2
SecondaryNumber of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase
Time frame:
Weeks 0, 10 and 16 weeks after the last dose of study drug in induction phase
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase
ParticipantsInduction Phase: Vedolizumab, 300 mg
Week 00
Week 101
16 Weeks After Last Administration0
SecondaryNumber of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
Time frame:
Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug in maintenance phase
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
ParticipantsMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: Placebo
Week 000
Week 1000
Week 3002
Week 6001
16 Weeks After Last Administration00
SecondaryNumber of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Open Label Cohort
Time frame:
Weeks 0, 10, 30, 62, 94 and 16 weeks after the last dose of study drug in open-label cohort
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Open Label Cohort
ParticipantsOpen-Label: Vedolizumab 300 mg
Week 02
Week 102
Week 301
Week 620
Week 940
16 Weeks After Last Administration2

Adverse events

Collected over From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Phase: Vedolizumab, 300 mg0/79 (0%)8/79 (10.1%)17/79 (21.5%)
Induction Phase: Placebo0/78 (0%)10/78 (12.8%)19/78 (24.4%)
Maintenance Phase: Vedolizumab 300 mg0/12 (0%)2/12 (16.7%)9/12 (75%)
Maintenance Phase: Placebo0/12 (0%)4/12 (33.3%)7/12 (58.3%)
Maintenance Phase: Placebo Continuation0/17 (0%)2/17 (11.8%)12/17 (70.6%)
Open-Label: Vedolizumab 300 mg0/134 (0%)70/134 (52.2%)113/134 (84.3%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
Crohn's diseaseGastrointestinal disorders2/7910/781/122/121/1735/134
SubileusGastrointestinal disorders1/790/780/121/120/171/134
Abdominal adhesionsGastrointestinal disorders0/790/781/120/120/171/134
Erythema nodosumSkin and subcutaneous tissue disorders0/790/780/121/120/170/134
CellulitisInfections and infestations0/790/780/120/121/170/134
Intestinal obstructionGastrointestinal disorders1/790/780/120/120/174/134
Anal abscessInfections and infestations1/790/780/120/120/174/134
IleusGastrointestinal disorders0/790/780/120/120/173/134
Intestinal stenosisGastrointestinal disorders0/790/780/120/120/173/134
Anal fistulaGastrointestinal disorders0/791/780/120/120/172/134
Most frequent other events
Showing 10 of 48
Most frequent other events
EventInduction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboMaintenance Phase: Vedolizumab 300 mgMaintenance Phase: PlaceboMaintenance Phase: Placebo ContinuationOpen-Label: Vedolizumab 300 mg
NasopharyngitisInfections and infestations11/7911/784/124/124/1755/134
Crohn's diseaseGastrointestinal disorders0/795/780/120/122/1727/134
PyrexiaGeneral disorders0/790/780/121/121/1719/134
InfluenzaInfections and infestations0/790/780/120/120/1716/134
ConjunctivitisInfections and infestations0/790/780/120/122/170/134
Dental cariesGastrointestinal disorders0/790/780/120/121/1715/134
AnaemiaBlood and lymphatic system disorders0/790/780/120/120/1713/134
Iron deficiency anaemiaBlood and lymphatic system disorders0/790/781/120/120/170/134
DiarrhoeaGastrointestinal disorders0/790/780/121/121/170/134
Abdominal pain upperGastrointestinal disorders0/790/780/121/120/179/134

Baseline characteristics

All participants who entered in the induction phase.

Age, Continuous
Age, Continuous(years)Induction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboTotal
Mean33.9 ± 12.2532.6 ± 10.9333.3 ± 11.60
Sex: Female, Male
Sex: Female, Male(Participants)Induction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboTotal
Female282654
Male5152103
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Induction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Induction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboTotal
Japan7978157
Height
Height(cm)Induction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboTotal
Mean166.3 ± 8.73166.4 ± 7.97166.4 ± 8.33
Weight
Weight(kg)Induction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboTotal
Mean58.53 ± 14.09555.03 ± 8.92856.79 ± 11.906
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Induction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboTotal
Mean21.15 ± 4.94219.81 ± 2.56720.48 ± 3.989
Duration of Crohn's Disease
Duration of Crohn's Disease(years)Induction Phase: Vedolizumab, 300 mgInduction Phase: PlaceboTotal
Median7.20 (0.3 to 27.8)8.35 (0.3 to 32.0)7.90 (0.3 to 32.0)

8 further baseline measures are reported on the registry.

08

Study locations

56 sites
  • Nagoya, Aichi, Japan
  • Toyota, Aichi, Japan
  • Hirosaki, Aomori, Japan
  • Abiko, Chiba, Japan
  • Kashiwa, Chiba, Japan
  • Sakura, Chiba, Japan
  • Matsuyama, Ehime, Japan
  • Chikushino, Fukuoka, Japan
  • Kasuga, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Takasaki, Gunma, Japan
  • Fukuyama, Hiroshima, Japan
  • Hatsukaichi, Hiroshima, Japan
  • Asahikawa, Hokkaido, Japan
  • Sapporo, Hokkaido, Japan
  • Tomakomai, Hokkaido, Japan
  • Akashi, Hyogo, Japan
  • Nishinomiya, Hyogo, Japan
  • Takamatsu, Kagawa, Japan
  • Kamakura, Kanagawa, Japan
  • Kawasaki, Kanagawa, Japan
  • Sagamihara, Kanagawa, Japan
  • Yokohama, Kanagawa, Japan
  • Kochi-shi, Kochi, Japan
  • Sendai, Miyagi, Japan
  • Kurashiki, Okayama, Japan
  • Moriguchi, Osaka, Japan
  • Suita, Osaka, Japan
  • Tokorozawa, Saitama, Japan
  • Otsu, Shiga, Japan
  • Hamamatsu, Shizuoka, Japan
  • Shimotsuke, Tochigi, Japan
  • Adachi-ku, Tokyo, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Chiyoda-ku, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Shinagawa-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Shunan, Yamaguchi, Japan
  • Kofu, Yamanashi, Japan
  • Chiba, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Hiroshima, Japan
  • Kagoshima, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Nagasaki, Japan
  • Niigata, Japan
  • Oita, Japan
  • Okayama, Japan
  • Okinawa, Japan
  • Osaka, Japan
  • Saga, Japan
  • Saitama, Japan
  • Wakayama, Japan
09

References and documents

Publications

  • Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res. 2021 Jan;19(1):95-105. doi: 10.5217/ir.2019.09167. Epub 2020 Jul 10. PubMed 32635680 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Jan 2019, 59 months.

Results were first posted in Dec 2019, 10 months after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 59 months is above that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2014
First posted
Jan 17, 2014
StartActual
Jan 28, 2014
Primary completionActual
Jan 25, 2019
CompletionActual
May 21, 2019
Results first posted
Dec 9, 2019
Last update
Dec 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02038920
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 17, 2014
Start date
Jan 28, 2014
Primary completion
Jan 25, 2019
Completion
May 21, 2019
Results posted
Dec 9, 2019
Last update
Dec 9, 2019

Study contacts

Study Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion